1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Sep 2023
Admin
News Article

Chinese startups Cure Genetics and Frametact ink $60 M deal to develop gene therapy for familial neurological diseases

China-based startup Cure Genetics and Frametact, founded by a molecular neuroscience research team at The Hong Kong University of Science and Technology and Hong Kong Center For Neurodegenerative Diseases, have jointly announce the signing of a collaborative development and licensing agreement.

The partnership will leverage Cure Genetics' proprietary VELP™ platform to develop novel Adeno-Associated Virus (AAV) vectors for the treatment of familial neurological diseases.

According to the agreement, Cure Genetics will receive an upfront and milestone payment totaling $60 million. Additionally, upon the market launch of the product, Cure Genetics will continue to receive sales royalties based on net revenue.

This collaboration will leverage the extensive expertise of Frametact in the domain of neurological diseases, combined with Cure Genetics' leading technology in AAV vector development and efficient in vivo AAV screening. Together, the companies will work on developing treatments for familial neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease.

This collaboration, following a previous partnership with Boehringer Ingelheim, marks another significant step forward for Cure Genetics with a globally leading organisation. It not only validates the global advancement of the VELP™ platform but also signifies a leap forward in Cure Genetics' internationalisation process.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!